Page last updated: 2024-10-16

gamma-aminobutyric acid and Diabetes Mellitus

gamma-aminobutyric acid has been researched along with Diabetes Mellitus in 21 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.

Research Excerpts

ExcerptRelevanceReference
"We hypothesized that the addition of coenzyme Q10 (CoQ10) to pregabalin might be helpful in improving symptoms in patients suffering from painful diabetic neuropathy (PDN)."9.51Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022)
"On the intent‑to‑treat population (ITT) analysis, the CoQ10 + pregabalin regimen resulted in significantly greater pain relief than the placebo + pregabalin regimen."9.51Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022)
"The important pathological consequences of insulin resistance arise from the detrimental effects of accumulated long-chain fatty acids and their respective acylcarnitines."7.83Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance. ( Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Svalbe, B; Volska, K, 2016)
" Besides pregabalin (150 mg/day), the patients, upon their group assignment, received CoQ10 at a dosage of 100 mg every 8 h or matched placebo for 8 consecutive weeks."7.11Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022)
"We hypothesized that the addition of coenzyme Q10 (CoQ10) to pregabalin might be helpful in improving symptoms in patients suffering from painful diabetic neuropathy (PDN)."5.51Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022)
"On the intent‑to‑treat population (ITT) analysis, the CoQ10 + pregabalin regimen resulted in significantly greater pain relief than the placebo + pregabalin regimen."5.51Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022)
"The important pathological consequences of insulin resistance arise from the detrimental effects of accumulated long-chain fatty acids and their respective acylcarnitines."3.83Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance. ( Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Svalbe, B; Volska, K, 2016)
"Diabetic peripheral neuropathic pain (DPNP) is common and often distressing."3.11Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomise ( Ahmed, SH; Alam, U; Bennett, DL; Bouhassira, D; Bradburn, M; Cooper, C; Devers, M; Gandhi, R; Glover, R; Gouni, R; Hariman, C; Horspool, M; Johnson, M; Jude, EB; Julious, S; Loban, A; Maguire, D; McDougall, C; Petrie, J; Rajbhandari, S; Rayman, G; Rice, ASC; Selvarajah, D; Sharma, S; Sloan, G; Sutherland, K; Tesfaye, S; Tsatlidis, V; Turton, E; Vas, P; Waterhouse, S; White, D, 2022)
" Besides pregabalin (150 mg/day), the patients, upon their group assignment, received CoQ10 at a dosage of 100 mg every 8 h or matched placebo for 8 consecutive weeks."3.11Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022)
"The study did not provide any evidence of clinical efficacy for AZD5213 when combined with pregabalin in the treatment of painful diabetic neuropathy."3.01A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability. ( Alexander, RC; Katz, N; Raudibaugh, K; Spierings, ELH, 2021)
"In this study, patients with painful diabetic neuropathy were trained using an experimental pain paradigm in an attempt to enroll a subset of patients who are "pain connoisseurs" and therefore more able to discriminate between active and placebo treatments."3.01A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability. ( Alexander, RC; Katz, N; Raudibaugh, K; Spierings, ELH, 2021)
"Type 1 diabetes is characterized by the destruction of pancreatic β cells, and generating new insulin-producing cells from other cell types is a major aim of regenerative medicine."1.46Artemisinins Target GABA ( Avolio, F; Baburin, I; Barbieux, C; Bennett, KL; Berishvili, E; Bock, C; Briand, F; Casteels, T; Colinge, J; Collombat, P; Courtney, M; Distel, M; Farlik, M; Frogne, T; Gridling, M; Harkany, T; Hecksher-Sørensen, J; Hering, S; Honoré, C; Huber, KVM; Ingvorsen, C; Kimmel, RA; Klughammer, J; Kubicek, S; Lardeau, CH; Li, J; Májek, P; Meyer, D; Parapatics, K; Pauler, FM; Penz, T; Romanov, RA; Schmitner, N; Sdelci, S; Spittler, A; Stukalov, A; Sturtzel, C; Sulpice, T; Superti-Furga, G; Vieira, A, 2017)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19902 (9.52)18.7374
1990's1 (4.76)18.2507
2000's3 (14.29)29.6817
2010's7 (33.33)24.3611
2020's8 (38.10)2.80

Authors

AuthorsStudies
Zhou, H1
Rao, Z1
Zhang, Z2
Zhou, J1
Tesfaye, S1
Sloan, G1
Petrie, J1
White, D1
Bradburn, M1
Julious, S1
Rajbhandari, S1
Sharma, S1
Rayman, G1
Gouni, R1
Alam, U1
Cooper, C1
Loban, A1
Sutherland, K1
Glover, R1
Waterhouse, S1
Turton, E1
Horspool, M1
Gandhi, R1
Maguire, D1
Jude, EB1
Ahmed, SH1
Vas, P1
Hariman, C1
McDougall, C1
Devers, M1
Tsatlidis, V1
Johnson, M1
Rice, ASC1
Bouhassira, D1
Bennett, DL1
Selvarajah, D1
Amini, P1
Sajedi, F1
Mirjalili, M1
Mohammadi, Y1
Mehrpooya, M1
Dhanani, LY1
Totton, RR1
Jara-Quijada, E1
Pérez-Won, M1
Tabilo-Munizaga, G1
Lemus-Mondaca, R1
González-Cavieres, L1
Palma-Acevedo, A1
Herrera-Lavados, C1
Milovanovic, S1
Grzegorczyk, A1
Świątek, Ł1
Grzęda, A1
Dębczak, A1
Tyskiewicz, K1
Konkol, M1
Li, Y3
Chang, P1
Sankaran, S1
Jang, H1
Nie, Y1
Zeng, A1
Hussain, S1
Wu, JY1
Chen, X3
Shi, L2
Senapati, A1
Chetri, BK1
Mitra, S1
Shelke, RG1
Rangan, L1
Chauhan, AS1
Tiwari, M1
Indoliya, Y1
Mishra, SK1
Lavania, UC1
Chauhan, PS1
Chakrabarty, D1
Tripathi, RD1
Akaputra, R1
Hatta, M1
Massi, MN1
Djaharuddin, I1
Bukhari, A1
Aminuddin, A1
Santoso, A1
Natzir, R1
Bahar, B1
Fachri, M1
Farsida, F1
Fathimah, A1
Ubaidah, FM1
Sridiana, E1
Dwiyanti, R1
Syukri, A1
Junita, AR1
Febrianti, A1
Primaguna, MR1
Azhar, A1
Rajaure, YS1
Thapa, B1
Budhathoki, L1
Rana, SR1
Khadka, M1
Batchu, UR1
Surapaneni, JR1
Cheemalamarri, C1
Mandava, K1
Puvvada, N1
Shetty, PR1
Mv, S1
Ranjbarian, P1
Goudarzi, F1
Akya, A1
Heidarinia, H1
Farasat, A1
Rostamian, M1
Suri, K1
Rajput, N1
Sharma, P1
Omble, AD1
Kulkarni, K1
Gahlay, GK1
Fernandez Garcia, E1
Paudel, U1
Noji, MC1
Bowman, CE1
Rustgi, AK1
Pitarresi, JR1
Wellen, KE1
Arany, Z1
Weissenrieder, JS1
Foskett, JK1
Lee, MS1
Han, HJ1
Choi, TI1
Lee, KH1
Baasankhuu, A1
Kim, HT1
Kim, CH1
Redd, PS1
Payero, L1
Gilbert, DM1
Page, CA1
King, R1
McAssey, EV1
Bodie, D1
Diaz, S1
Hancock, CN1
Lee, HS1
Jung, S1
Lee, SW1
Kim, YT1
Lee, J1
Ren, T1
Yu, Z1
Yu, H1
Deng, K1
Wang, Z1
Li, X1
Wang, H1
Wang, L2
Xu, Y1
Lascano, J1
Riley, L1
Khodayari, N1
Brantly, M1
Gupta, R1
Pradhan, J1
Haldar, A1
Murapaka, C1
Chandra Mondal, P1
Gao, R1
Dai, TY1
Meng, Z1
Sun, XF1
Liu, DX1
Shi, MM1
Li, HR1
Kang, X1
Bi, B1
Zhang, YT1
Xu, TW1
Yan, JM1
Jiang, Q1
Helmchen, G1
Guo, H1
Xiang, W1
Fang, Y1
Li, J5
Lin, Y1
An, X1
Jiang, D1
Cao, Q2
Xu, F1
Shiigi, H1
Wang, W1
Chen, Z1
Akosman, I1
Kumar, N1
Mortenson, R1
Lans, A1
De La Garza Ramos, R1
Eleswarapu, A1
Yassari, R1
Fourman, MS1
Jana, S1
Evans, EGB1
Jang, HS1
Zhang, S2
Zhang, H1
Rajca, A1
Gordon, SE1
Zagotta, WN1
Stoll, S1
Mehl, RA1
Miller, S1
Lee, DA1
Muhimpundu, S1
Maxwell, CA1
Liu, Z1
Shen, F1
Tong, Q1
Tang, M1
Peng, M1
Jiao, Z1
Jiang, Y1
Ao, L1
Fu, W1
Lv, X1
Jiang, G1
Hou, L1
Tu, WC1
McManamen, AM1
Su, X1
Jeacopello, I1
Takezawa, MG1
Hieber, DL1
Hassan, GW1
Lee, UN1
Anana, EV1
Locknane, MP1
Stephenson, MW1
Shinkawa, VAM1
Wald, ER1
DeMuri, GP1
Adams, KN1
Berthier, E1
Thongpang, S1
Theberge, AB1
Jiang, L1
Li, Z1
Dong, Q1
Rong, X1
Dong, G1
Huang, J1
Liang, Y1
Sun, S1
Zhang, R1
Miao, Z1
Senju, C1
Nakazawa, Y1
Oso, T1
Shimada, M1
Kato, K1
Matsuse, M1
Tsujimoto, M1
Masaki, T1
Miyazaki, Y1
Fukushima, S1
Tateishi, S1
Utani, A1
Murota, H1
Tanaka, K1
Mitsutake, N1
Moriwaki, S1
Nishigori, C1
Ogi, T1
Liu, C1
Zhang, X1
Wang, B1
Luo, Z1
Qian, D1
Liu, J1
Waterhouse, GIN1
Barbosa, M1
Marques-Sá, J1
Carvalho, C1
Fernandes, V1
Grilli, D1
Smetana, V1
Ahmed, SJ1
Shtender, V1
Pani, M1
Manfrinetti, P1
Mudring, AV1
Kuang, Y1
Yang, D1
Gai, S1
He, F1
An, B1
Yang, P1
Notini, L1
Schulz, K1
Kubeneck, LJ1
Grigg, ARC1
Rothwell, KA1
Fantappiè, G1
ThomasArrigo, LK1
Kretzschmar, R1
Siswanto, FM1
Okukawa, K1
Tamura, A1
Oguro, A1
Imaoka, S1
Kim, CG1
Jung, M1
Kim, HS1
Lee, CK1
Jeung, HC1
Koo, DH1
Bae, WK1
Zang, DY1
Kim, BJ1
Kim, H1
Yun, UJ1
Che, J1
Park, S1
Kim, TS1
Kwon, WS1
Park, J1
Cho, SW1
Nam, CM1
Chung, HC1
Rha, SY1
Colombo, N1
Van Gorp, T1
Matulonis, UA1
Oaknin, A1
Grisham, RN1
Fleming, GF1
Olawaiye, AB1
Nguyen, DD1
Greenstein, AE1
Custodio, JM1
Pashova, HI1
Tudor, IC1
Lorusso, D1
Zhou, F1
Jiang, Z1
Liang, H1
Ru, S1
Bettiol, AA1
Gao, W1
Lipsyc-Sharf, M1
Jain, E1
Collins, LC1
Rosenberg, SM1
Ruddy, KJ1
Tamimi, RM1
Schapira, L1
Come, SE1
Peppercorn, JM1
Borges, VF1
Warner, E1
Snow, C1
Krop, IE1
Kim, D1
Weiss, J1
Zanudo, JGT1
Partridge, AH1
Wagle, N1
Waks, AG1
Moskowitz, A1
Berg, KM1
Grossestreuer, AV1
Balaji, L1
Liu, X1
Cocchi, MN1
Chase, M1
Gong, MN1
Gong, J1
Parikh, SM1
Ngo, L1
Berlin, N1
Donnino, MW1
Zhou, Y1
Chen, Q1
Zhong, S1
Liu, H1
Koh, K1
Chen, H1
He, J1
Chen, J1
Liu, S1
Lin, L1
Zhang, Y1
Xiao, S1
Cao, S1
Yan, B2
Deng, J1
Gu, J1
Tao, Y1
Huang, C1
Lai, C1
Yong, Q1
Shen, Y1
Gong, Z1
Cao, J1
Mao, W1
Yao, Y1
Zhao, J1
Li, Q1
Liu, K1
Liu, B1
Feng, S1
Chandran, V1
Kunjan, C1
Veerapandian, V1
Kannan, R1
Zhang, T1
von Gunten, U1
Caruso, FR1
Goulart, CDL1
Jr, JCB1
de Oliveira, CR1
Mendes, RG1
Arena, R1
Borghi-Silva, A1
Carrasco-Nuñes, N1
Romano, M1
Cabeza, M1
Jiang, B1
Chen, D1
Zhao, C1
Ma, Y1
Yang, W1
Shen, X1
Satheeshkumar, K1
Saravanakumar, P1
Kalavathi, A1
Vennila, KN1
Elango, KP1
Mues Genannt Koers, L1
Prevost, D1
Paulssen, E1
Hoehr, C1
Ulhassan, Z1
Yang, S1
He, D1
Khan, AR1
Salam, A1
Azhar, W1
Muhammad, S1
Ali, S1
Hamid, Y1
Khan, I1
Sheteiwy, MS1
Zhou, W1
Wang, X1
Xie, Q1
Wang, Y1
Lü, H1
Fu, M1
Wang, D1
Sun, Y1
Huang, Y1
Lu, T1
Ma, H1
Moss, TT1
Stavem, K1
Aandahl, A1
Gløersen, AS1
Grønberg, BH1
Neumann, K1
Vedeler, CA1
Lundqvist, C1
Alexander, RC1
Raudibaugh, K1
Spierings, ELH1
Katz, N1
Liu, W1
Lau, HK1
Son, DO1
Jin, T1
Yang, Y1
Prud'homme, GJ1
Wang, Q1
Cobin, RH1
Goodman, NF1
Galuppo, M1
Giacoppo, S1
Bramanti, P1
Mazzon, E1
Scholl, JH1
van Eekeren, R1
van Puijenbroek, EP1
Liepinsh, E1
Makrecka-Kuka, M1
Makarova, E1
Volska, K1
Svalbe, B1
Sevostjanovs, E1
Grinberga, S1
Kuka, J1
Dambrova, M1
Larsson, M1
Lietzau, G1
Nathanson, D1
Östenson, CG1
Mallard, C1
Johansson, ME1
Nyström, T1
Patrone, C1
Darsalia, V1
Ben-Othman, N1
Vieira, A2
Courtney, M2
Record, F1
Gjernes, E1
Avolio, F2
Hadzic, B1
Druelle, N1
Napolitano, T1
Navarro-Sanz, S1
Silvano, S1
Al-Hasani, K1
Pfeifer, A1
Lacas-Gervais, S1
Leuckx, G1
Marroquí, L1
Thévenet, J1
Madsen, OD1
Eizirik, DL1
Heimberg, H1
Kerr-Conte, J1
Pattou, F1
Mansouri, A1
Collombat, P2
Casteels, T1
Frogne, T1
Ingvorsen, C1
Honoré, C1
Huber, KVM1
Schmitner, N1
Kimmel, RA1
Romanov, RA1
Sturtzel, C1
Lardeau, CH1
Klughammer, J1
Farlik, M1
Sdelci, S1
Briand, F1
Baburin, I1
Májek, P1
Pauler, FM1
Penz, T1
Stukalov, A1
Gridling, M1
Parapatics, K1
Barbieux, C1
Berishvili, E1
Spittler, A1
Colinge, J1
Bennett, KL1
Hering, S1
Sulpice, T1
Bock, C1
Distel, M1
Harkany, T1
Meyer, D1
Superti-Furga, G1
Hecksher-Sørensen, J1
Kubicek, S1
Gomez, R1
Vargas, CR1
Wajner, M1
Barros, HM1
Nagai, C1
Pipili, C1
Cholongitas, E1
Lernmark, A1
Siebert, G1
Gessner, B1
Klasser, M1
Martin, RJ1
Jeanrenaud, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Connective Tissue Manipulation on Menopausal Symptoms[NCT05293860]58 participants (Anticipated)Interventional2022-04-04Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for gamma-aminobutyric acid and Diabetes Mellitus

ArticleYear
Function of the GABAergic System in Diabetic Encephalopathy.
    Cellular and molecular neurobiology, 2023, Volume: 43, Issue:2

    Topics: Adult; Animals; Blood Glucose; Brain Diseases; Diabetes Mellitus; gamma-Aminobutyric Acid; Humans; H

2023
Use of natural compounds in the management of diabetic peripheral neuropathy.
    Molecules (Basel, Switzerland), 2014, Mar-05, Volume: 19, Issue:3

    Topics: Alkaloids; Amines; Animals; Biological Products; Cannabinoids; Complementary Therapies; Cyclohexanec

2014
[Progress in diagnosis of and therapy for diabetic choreic movement and ballismus].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Aug-10, Volume: 93, Issue:8

    Topics: Anti-Dyskinesia Agents; Basal Ganglia; Chorea; Diabetes Complications; Diabetes Mellitus; Dyskinesia

2004
Glutamic acid decarboxylase--gene to antigen to disease.
    Journal of internal medicine, 1996, Volume: 240, Issue:5

    Topics: Animals; Autoantibodies; Autoimmune Diseases; Autoimmunity; Diabetes Mellitus; gamma-Aminobutyric Ac

1996
Energy supply of the central nervous system.
    Bibliotheca nutritio et dieta, 1986, Issue:38

    Topics: Blood-Brain Barrier; Brain; Calorimetry; Diabetes Mellitus; Electroencephalography; Energy Metabolis

1986

Trials

4 trials available for gamma-aminobutyric acid and Diabetes Mellitus

ArticleYear
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomise
    Lancet (London, England), 2022, 08-27, Volume: 400, Issue:10353

    Topics: Amitriptyline; Analgesics; Cross-Over Studies; Diabetes Mellitus; Diabetic Neuropathies; Double-Blin

2022
Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:12

    Topics: Analgesics; Diabetes Mellitus; Diabetic Neuropathies; Double-Blind Method; gamma-Aminobutyric Acid;

2022
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Sexuality research & social policy : journal of NSRC : SR & SP, 2023, Apr-05

    Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Com

2023
A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability.
    The Clinical journal of pain, 2021, Volume: 37, Issue:1

    Topics: Analgesics; Cross-Over Studies; Diabetes Mellitus; Diabetic Neuropathies; gamma-Aminobutyric Acid; H

2021

Other Studies

12 other studies available for gamma-aminobutyric acid and Diabetes Mellitus

ArticleYear
Mechanistic study on the inhibition of α-amylase and α-glucosidase using the extract of ultrasound-treated coffee leaves.
    Journal of the science of food and agriculture, 2024, Jan-15, Volume: 104, Issue:1

    Topics: alpha-Amylases; alpha-Glucosidases; Amino Acids; Coffea; Diabetes Mellitus; gamma-Aminobutyric Acid;

2024
Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Aged; Antibodies, Monoclonal; Autoantibodies; Diabetes Mellitus; Encephalitis; gamma-Aminobutyric Ac

2023
Combined use of GABA and sitagliptin promotes human β-cell proliferation and reduces apoptosis.
    The Journal of endocrinology, 2021, Volume: 248, Issue:2

    Topics: Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus; Dipeptidyl-Peptidase IV In

2021
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7

    Topics: Administration, Cutaneous; Administration, Oral; Aged; Amines; Breast Neoplasms; Cardiovascular Dise

2017
Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients.
    British journal of clinical pharmacology, 2015, Volume: 79, Issue:5

    Topics: Amines; Analgesics; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus; Gabapentin; gamma

2015
Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance.
    Pharmacological research, 2016, Volume: 113, Issue:Pt B

    Topics: Animals; Blood Glucose; Carnitine; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diet, High-Fa

2016
Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4.
    Bioscience reports, 2016, Volume: 36, Issue:6

    Topics: Animals; Calbindin 2; Calbindins; Corpus Striatum; Diabetes Mellitus; Diabetes Mellitus, Experimenta

2016
Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis.
    Cell, 2017, Jan-12, Volume: 168, Issue:1-2

    Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Diabetes Mellitus; gamm

2017
Artemisinins Target GABA
    Cell, 2017, Jan-12, Volume: 168, Issue:1-2

    Topics: Animals; Artemether; Artemisinins; Carrier Proteins; Cell Transdifferentiation; Cells, Cultured; Dia

2017
Lower in vivo brain extracellular GABA concentration in diabetic rats during forced swimming.
    Brain research, 2003, Apr-11, Volume: 968, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Behavior, Animal; Diabetes Mellitus; Disease Models, Animal; Extrace

2003
Erythromelalgia in a diabetic patient managed with gabapentin.
    Diabetes research and clinical practice, 2008, Volume: 79, Issue:3

    Topics: Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Complications; Diabetes

2008
Growth hormone in obesity and diabetes: inappropriate hypothalamic control of secretion.
    International journal of obesity, 1985, Volume: 9 Suppl 1

    Topics: Animals; Bicuculline; Blood Glucose; Diabetes Mellitus; gamma-Aminobutyric Acid; Growth Hormone; Hyp

1985